VivoSeq
Musculoskeletal

Marfan Syndrome

9

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Marfan syndrome is an early-stage landscape with 9 programs across 6 companies. The most active players are Merck & Co., Institut de Recherches Internationales Servier, Servier. 4 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

0/100

Mech. Concentration

43/100

Completion Rate

86/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 3Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier

1 program

Phase 3S

Servier

1 program

Phase 3Sanofi logo

Sanofi

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedV

Val Adams

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

10

clinical trials

Completed6 · 60%
Unknown status2 · 20%
Terminated1 · 10%
Active, not recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Transcriptomic Study of Adult Population With Marfan Syndrome
Active, not recruiting·IIRCCS Policlinico S. Donato·N/A·NCT05700175·99 enrolled
Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome
Completed·BBayside Health·Phase 3·NCT00485368·17 enrolled
Comparison of Medical Therapies in Marfan Syndrome.
Completed·—·Phase 4·NCT01295047·18 enrolled
Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers
Completed·UUniversity Hospital, Ghent·Phase 3·NCT00782327·22 enrolled
Losartan Versus Atenolol for the Treatment of Marfan Syndrome
Completed·UUniversity of British Columbia·Phase 2·NCT00593710·17 enrolled
Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome
Completed·CCarelon Research·Phase 3·NCT00429364·608 enrolled
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
Completed·—·Phase 3·NCT00723801·40 enrolled
Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome
Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00763893·303 enrolled
A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome
Unknown status·NNational Taiwan University Hospital·Phase 2·NCT00651235·44 enrolled
Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome
Unknown status·—·Phase 3·NCT01145612·140 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)